

EMR Resource for: EPIC® BRUKINSA® in Chronic Lymphocytic Leukemia (CLL)



Objective: Identify, assess, and track CLL patients eligible for BRUKINSA therapy.



STEP 1: RUN A REPORT

To identify all CLL patients within Epic EMR:

1 SEARCH KEYWORDS:

Use search terms like “chronic lymphocytic leukemia” or “CLL” in diagnosis codes, problem list, or past medical history.

2 WORK WITH SUPPORT:

- › Collaborate with the Epic Support Team to create a custom report or Registry to flag patients with CLL.
- › Alternatively, engage your Information Technology (IT) Department for assistance with data pulls or custom patient lists.

3 OPTIONAL FILTERS:

- › ICD-10 code: C91.1X (Chronic lymphocytic leukemia)
- › Disease stage (if documented)
- › Prior treatments (e.g., ibrutinib, venetoclax)
- › Comorbidities or lab markers (e.g., cytogenetics, TP53 status)





STEP 2: REVIEW CHART FOR BRUKINSA ELIGIBILITY

Once you have a list of potential patients:

1 CLINICAL CRITERIA FOR BRUKINSA:

- › Diagnosis of relapsed/refractory or treatment-naïve CLL
- › Consider prior BTK inhibitor use without progression or intolerance
- › Evaluate age, comorbidities, and cardiovascular risk
- › Look for relevant molecular markers: TP53 mutation, del(17p)

2 SUGGESTED DATA TO REVIEW IN PROGRESS/VISIT NOTES:

- › Current therapy status
- › Lab results (CBC, lymphocyte count, TP53/FISH panel)
- › Cardiac risk factors (to support choice of BTKi with lower atrial fibrillation risk)
- › History of intolerance to other BTKis (headaches)

3 USE CLINICAL DECISION SUPPORT

Clinical Decision Support (CDS) or Chart Review Tools in Epic to extract these elements if available.



STEP 3: Create Reminders & Track Milestones

1 WORK WITH EPIC SUPPORT OR CLINICAL INFORMATICIST TO:

- › Integrate reminders or best practice advisories (BPAs) when eligible patients are seen
- › Use the Treatment Plan or build a custom Protocol for BRUKINSA tracking

2 TRACK KEY MILESTONES:

- › Treatment initiation and response assessments
- › Tolerability and AE management
- › Disease monitoring intervals

3 FLAG PATIENTS DUE FOR:

- › Reassessment of BTKi eligibility
- › Genetic retesting or FISH panel if outdated
- › Follow-up visit for therapy adjustment



ADDITIONAL TIPS

Develop a Pharmacy Triage SmartPhrase

- › Use a .BRUKINSAELIGIBILITY SmartPhrase to document key eligibility factors

Create a BRUKINSA-Specific SmartSet

- › Develop a SmartSet for initiating BRUKINSA
- › Use this SmartSet to streamline workflows during clinic visits

Incorporate into Disease Pathways or Protocols

- › Embedding BRUKINSA into pathways and protocols can help ensure that it is considered at every appropriate decision point during the care of CLL patients